New sequencing tool speeds up SARS-CoV-2 outbreak response and informs treatment

Announcing a new article publication for Zoonoses journal. In the context of two Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) outbreaks involving local transmission and an international flight, the authors of this article used meta-transcriptome and multi-amplicon sequencing to successfully acquire the complete viral genome sequences from clinical samples with varying viral loads.
To enhance viral transcript presence, a primer pool was used for reverse transcription and the samples were sequenced with nanopore sequencing, and the entire genomic sequence of the virus was successfully acquired within less than 4 hours. In a substantial sample size of approximately 800 clinical specimens, different sequencing methods were thoroughly examined and compared.

Meta-transcriptome sequencing was effective for samples with viral reverse transcription polymerase chain reaction (RT-PCR) threshold cycle (Ct) values below 22, whereas multi-amplicon sequencing was effective across a wide Ct range. Additionally, enriched nanopore sequencing was valuable in capturing the complete genome sequence when rapid results are required.

Through monitoring the viral quasi-species in individual patients, ongoing viral evolution during neutralizing antibody therapy was observed and evidence was found that vaccine administration may affect the development of viral quasi-species. Overall, the findings highlight the potential of this viral sequencing strategy for both outbreak control and patient treatment.

Source:
Journal reference:

Li, Z., et al. (2024). Epidemiological Characteristics of Human Rabies in Urban and Suburban Districts in Shanghai, 2006–2021. Zoonoses. doi.org/10.15212/zoonoses-2023-0038.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR